Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Olema Pharmaceuticals, Inc. OLMA
$7.10
+$0.31 (4.41%)
На 18:03, 12 мая 2023
Ранг: 3
Ключевые показатели
-
Marketcap
293461420.00000000
-
week52high
7.42
-
week52low
2.00
-
Revenue
0
-
P/E TTM
-3
-
Beta
2.28891400
-
EPS
-2.64000000
-
Last Dividend
0.00000000
-
Next Earnings Date
08 мая 2023 г. в 10:59
Описание компании
Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer. The company was formerly known as CombiThera, Inc. and changed its name to Olema Pharmaceuticals, Inc. in March 2009. Olema Pharmaceuticals, Inc. was incorporated in 2006 and is headquartered in San Francisco, California.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| HC Wainwright & Co. | Buy | Neutral | 10 июн 2022 г. |
| HC Wainwright & Co. | Neutral | 28 февр 2022 г. | |
| Canaccord Genuity | Buy | 14 дек 2020 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| Moriarty John B | A | 150000 | 150000 | 01 февр 2023 г. |
| Zojwalla Naseem | A | 150000 | 150000 | 01 февр 2023 г. |
| Bohen Sean | A | 550000 | 550000 | 01 февр 2023 г. |
| Horn Kinney | A | 150000 | 150000 | 01 февр 2023 г. |
| Kovacs Shane William Charles | A | 200000 | 200000 | 01 февр 2023 г. |
| Myles David C. | A | 150000 | 150000 | 01 февр 2023 г. |
| Harmon Cyrus | A | 150000 | 150000 | 01 февр 2023 г. |
| Bohen Sean | A | 74279 | 20000 | 21 сент 2022 г. |
| Bohen Sean | A | 74279 | 20000 | 21 сент 2022 г. |
| Kovacs Shane William Charles | A | 381197 | 20000 | 02 сент 2022 г. |
Новостная лента
Olema Oncology to Present at 41st Annual J.P. Morgan Healthcare Conference
GlobeNewsWire
03 янв 2023 г. в 07:00
SAN FRANCISCO, Jan. 03, 2023 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema”, “Olema Oncology”, Nasdaq: OLMA) today announced that Sean Bohen, M.D., President and Chief Executive Officer, will present at the 41st Annual J.P. Morgan Healthcare Conference in San Francisco, California, on Wednesday, January 11, 2023, at 2:15 p.m. PT (5:15 p.m. ET).
Olema Oncology to Present at H.C. Wainwright 24th Annual Global Investment Conference
GlobeNewsWire
06 сент 2022 г. в 16:30
SAN FRANCISCO, Sept. 06, 2022 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema,” “Olema Oncology” or the “Company,” Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for women's cancers, today announced that Shane Kovacs, Chief Operating and Financial Officer, will participate in a fireside chat at the H.C. Wainwright 24th Annual Global Investment Conference on Wednesday, September 14, 2022, at 2:30 p.m. ET (11:30 a.m. PT).
Olema Oncology to Present at Canaccord Genuity 42nd Annual Growth Conference
GlobeNewsWire
04 авг 2022 г. в 16:30
SAN FRANCISCO, Aug. 04, 2022 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology,” Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted therapies for women's cancers, today announced that Sean P. Bohen, M.D., Ph.D., President and Chief Executive Officer, will participate in a fireside chat at the Canaccord Genuity 42nd Annual Growth Conference on Thursday, August 11, 2022 at 1:30 p.m. ET.
Olema (OLMA) Up on FDA Fast Track Tag for Breast Cancer Drug
Zacks Investment Research
22 июл 2022 г. в 08:35
The FDA bestows a Fast Track designation to Olema's (OLMA) novel pipeline candidate, OP-1250, for the treatment of ER+/HER2- metastatic breast cancer. Stock up.